OTCMKTS:WINT - Windtree Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.8121 -3.19 (-79.71 %)
(As of 07/19/2018 02:03 AM ET)
Previous Close$4.00
Today's RangeN/A
52-Week Range$0.1775 - $5.81
VolumeN/A
Average Volume794 shs
Market Capitalization$15.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Windtree Therapeutics logoWindtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that has completed Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Receive WINT News and Ratings via Email

Sign-up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:WINT
CUSIP25466840
Phone215-488-9300

Debt

Debt-to-Equity Ratio-0.53
Current Ratio0.13
Quick Ratio0.13

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.48 million
Price / Sales2.07
Cash FlowN/A
Price / CashN/A
Book Value($7.57) per share
Price / Book-0.11

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-18,440,000.00
Net Margins-956.79%
Return on EquityN/A
Return on Assets-339.58%

Miscellaneous

Employees29
Outstanding Shares3,770,000
Market Cap$15.08

The Truth About Cryptocurrencies

Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions

What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics Inc (OTCMKTS:WINT) released its quarterly earnings data on Monday, May, 21st. The biotechnology company reported ($1.40) earnings per share for the quarter. The biotechnology company earned $0.20 million during the quarter. View Windtree Therapeutics' Earnings History.

What is the consensus analysts' recommendation for Windtree Therapeutics?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Windtree Therapeutics' key competitors?

Who are Windtree Therapeutics' key executives?

Windtree Therapeutics' management team includes the folowing people:
  • Mr. Craig E. Fraser, Pres, CEO & Director (Age 53)
  • Mr. John A. Tattory, Sr. VP, CFO & Treasurer (Age 52)
  • Dr. Steven G. Simonson, Sr. VP & Chief Medical Officer (Age 59)
  • Mr. George Cox, VP of Manufacturing & Supply Chain and Technical Operations (Age 66)
  • Ms. Mary B. Templeton, Sr. VP, Gen. Counsel & Corp. Sec. (Age 71)

Has Windtree Therapeutics been receiving favorable news coverage?

News headlines about WINT stock have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Windtree Therapeutics earned a news impact score of 0.17 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 43.46 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Windtree Therapeutics?

Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Windtree Therapeutics' stock price today?

One share of WINT stock can currently be purchased for approximately $0.8121.

How big of a company is Windtree Therapeutics?

Windtree Therapeutics has a market capitalization of $15.08 million and generates $1.48 million in revenue each year. Windtree Therapeutics employs 29 workers across the globe.

How can I contact Windtree Therapeutics?

Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]


MarketBeat Community Rating for Windtree Therapeutics (OTCMKTS WINT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe WINT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WINT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.